Skip to main content

Table 2 Comparison between Candida positive and negative groups

From: Candidiasis and other oral mucosal lesions during and after interferon therapy for HCV-related chronic liver diseases

   Total Goup 1 Group 2 P value
Subjects (n)   14 7 7  
Sex (M/F)   3/11 2/5 1/6 NS
Age (mean ± SD)   56.00 ± 12.94 61.30 ± 6.47 50.71 ± 16.00 NS
HCV genotype 1b 11 (78.57%) 6 (85.71%) 5 (71.43%) NS
  2a 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
  ND (serotype 2) 1 (7.14%) 0 (0%) 1 (14.29%) NS
HCV RNA level High 12 (85.71%) 6 (85.71%) 6 (85.71%) NS
  Low 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
Weight loss during IFN therapy   5.69 ± 4.57 8.71 ± 2.81 2.66 ± 4.00 0.0088
Neutrophil count (μ/L) Before IFN 2546.11 ± 793.47 2481.34 ± 599.67 2610.89 ± 997.36 NS
  2 weeks after IFN 1229.11 ± 590.25 1260.51 ± 473.58 1197.70 ± 726.82 NS
  3 months after IFN 1343.05 ± 584.48 1636.51 ± 670.69 1049.59 ± 298.98 NS
  6 months after IFN 1319.11 ± 301.15 1442.69 ± 194.15 1195.53 ± 350.95 NS
  End of treatment 1360.21 ± 547.74 1420.54 ± 401.41 1299.87 ± 693.13 NS
  6 months after treatment 2349.21 ± 695.36 2578.63 ± 716.47 2119.80 ± 641.48 NS
PLT (x10-4/μL) Before IFN 17.58 ± 7.06 17.54 ± 3.32 17.61 ± 9.84 NS
  2 weeks after IFN 14.04 ± 7.28 14.37 ±4.70 13.71 ± 9.61 NS
  3 months after IFN 13.69 ± 6.08 14.27 ± 5.36 13.11 ± 7.12 NS
  6 months after IFN 13.20 ± 5.31 14.21 ± 4.72 12.19 ± 6.03 NS
  End of treatment 14.45 ± 5.05 14.50 ± 4.59 14.40 ± 5.84 NS
  6 months after treatment 16.86 ± 6.03 18.14 ± 4.29 15.59 ± 7.52 NS
Hb (g/dL) Before IFN 13.97 ±1.08 13.91 ±1.26 14.03 ± 0.97 NS
  2 weeks after IFN 13.04 ±1.06 13.33± 1.34 12.76 ± 0.67 NS
  3 months after IFN 10.94 ±1.55 10.40 ±1.57 11.47 ±1.45 NS
  6 months after IFN 10.61 ±1.73 9.81 ± 1.45 11.41 ± 1.70 NS
  End of treatment 10.99 ±1.74 10.23 ± 1.89 11.74 ± 1.27 NS
  6 months after treatment 13.29 ±1.48 12.99 ± 2.05 13.59 ± 0.58 NS
Alb (g/dL) Before IFN 4.18 ± 0.35 4.10 ± 0.34 4.26 ± 0.36 NS
  2 weeks after IFN 3.76 ± 0.48 3.75 ± 0.38 3.76 ± 0.59 NS
  3 months after IFN 3.84 ± 0.37 3.76 ± 0.45 3.92 ± 0.28 NS
  6 months after IFN 3.88 ± 0.33 3.74 ± 0.42 4.02 ± 0.12 0.0550
  End of treatment 3.90 ± 0.38 3.77 ± 0.35 4.03 ± 0.39 NS
  6 months after treatment 4.27 ± 0.35 4.23 ± 0.34 4.30 ± 0.39 NS
Salivary flow (g/2 min) Before IFN 6.10 ± 1.81 5.86 ± 1.90 6.38 ± 1.81 NS
  2 weeks after IFN 5.71 ± 2.60 5.88 ± 2.33 5.55 ± 3.03 NS
  3 months after IFN 5.23 ± 2.14 4.92 ± 2.34 5.53 ± 2.06 NS
  6 months after IFN 5.42 ± 1.97 5.32 ± 2.14 5.51 ± 1.94 NS
  End of treatment 5.31 ± 2.06 5.33 ± 1.58 5.30 ± 2.58 NS
  6 months end of IFN 6.02 ± 1.81 6.03 ± 1.38 6.00 ± 2.28 NS
Diabetes mellitus positive, n (%) 2 (14.29%) 1 (14.29%) 1 (14.29%) NS
Oral mucosal lesions positive, n (%) 7 (50.00%) 6 (85.71%) 1 (14.29%) 0.0075
Steroid for external use positive, n (%) 6 (42.86%) 5 (71.43%) 1 (14.29%) 0.0308
Tooth-brushing after every meal yes, n (%) 8 (57.14%) 3 (42.86%) 5 (71.43%) NS
Denture wearer yes, n (%) 0 (0%) 0 (0%) 0 (0%) NS
Administration of antifungal agent yes, n (%) 2 (14.29%) 2 (28.57%) 0 (0%) NS
Effect of IFN therapy SVR , n (%) 11 (78.57%) 6 (85.71%) 5 (71.43%) NS
  1. HCV, hepatitis C virus; IFN, interferon; M, male; F, female; ND, not detected; NS, not significant; PLT, platelets; Hb, hemoglobin; Alb, albumin.